5 European Projects Found
Searched on 125080 European Projects
FINISHED
Imaging the Force of Cancer (FORCE)
Start date: Jan 1, 2016, End date: Dec 31, 2019,
Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Read Project
18
Partners Participants
FINISHED
Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex (EPISTOP)
Start date: Nov 1, 2013, End date: Oct 31, 2018,
Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usual ...
Read Project
16
Partners Participants
FINISHED
Local Immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages (IMMODGEL)
Start date: Oct 1, 2013, End date: Sep 30, 2017,
IMMODGEL aims to identify adverse immune reactions to dental and larynx titanium implants and to develop a novel therapeutic strategy to significantly decrease the implant and medical device failure caused by these reactions via design of an innovative immunomodulatory system. The system will be designed to be fixed to an implant via an adhesive polyelectrolyte multilayer and control the immune re ...
Read Project
9
Partners Participants
FINISHED
Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD)
Start date: Oct 1, 2011, End date: Sep 30, 2015,
"In 2010 a widely marketed drug for the treatment of type 2 diabetes (T2DM) (rosiglitazone) was taken from the market as it was associated with an increased risk of myocardial infarction, a T2DM complication it was actually supposed to prevent. This example shows several things. First, the approval requirements do not guarantee a longer term positive benefit risk profile. Second, large scale postm ...
Read Project
19
Partners Participants
FINISHED
Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)
Start date: Feb 1, 2010, End date: Jan 31, 2015,
CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these different studies would lead to an integrated appr ...
Read Project
